Cite

HARVARD Citation

    Johnson, L. et al. (n.d.). Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma. Journal for immunotherapy of cancer. p. . [Online]. 
  
Back to record